Who Exports Bromhexine from India — 288 Suppliers Behind a $16.3M Market
India's bromhexine export market is supplied by 288 active exporters who collectively shipped $16.3M across 1,945 shipments. UMAVIDA PHARMA PRIVATE LIMITED leads with a 16.1% market share, followed by EMCURE PHARMACEUTICALS LIMITED and MAXFORD HEALTHCARE. The top 5 suppliers together control 45.8% of total export value, reflecting a moderately competitive market structure.
Top Bromhexine Exporters from India — Ranked by Export Value
UMAVIDA PHARMA PRIVATE LIMITED is the leading bromhexine exporter from India, holding a 16.1% share of the $16.3M market across 1,945 shipments from 288 exporters. The top 5 suppliers — UMAVIDA PHARMA PRIVATE LIMITED, EMCURE PHARMACEUTICALS LIMITED, MAXFORD HEALTHCARE, J B CHEMICALS AND PHARMACEUTICALS LIMITED, AGIO PHARMACEUTICALS LIMITED — collectively control 45.8% of total export value, indicating a competitive market. Individual shares are: UMAVIDA PHARMA PRIVATE LIMITED (16.1%), EMCURE PHARMACEUTICALS LIMITED (13.1%), MAXFORD HEALTHCARE (5.8%), J B CHEMICALS AND PHARMACEUTICALS LIMITED (5.6%), AGIO PHARMACEUTICALS LIMITED (5.2%).
Top Bromhexine Exporters from India
Ranked by export value · 288 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | UMAVIDA PHARMA PRIVATE LIMITED TERBUTALINE SULPHATE, BROMHEXINE HYDROCHBROMHEXINE ORAL SOLUTION 4 MG / 5 ML (DABROMHEXINE HYDROCHLORIDE SYRUP 0.8 MG/ML | $2.6M | 1 | 16.1% |
| 2 | EMCURE PHARMACEUTICALS LIMITED GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDCOUGH MEDICINE CHESTY (BROMHEXINE HYDROC | $2.1M | 14 | 13.1% |
| 3 | MAXFORD HEALTHCARE BROMHEXINE SYRUP 4MG USP PACKING 60MLBROMHEXINE TAB 8MGPHARMA PRODUCTS:BROMHEXINE KIDDY BROMHE | $950.0K | 1 | 5.8% |
| 4 | J B CHEMICALS AND PHARMACEUTICALS LIMITED CETYLPYRIDINIUM CHLORIDE AND BROMHEXINE | $907.7K | 3 | 5.6% |
| 5 | AGIO PHARMACEUTICALS LIMITED KOFASMA SYRUP 200 MLKOFASMA SYRUP 100 MLKOFASMA SYRUP 200 ML (BROMHEXINE + GUAIF | $849.1K | 4 | 5.2% |
| 6 | LINCOLN PHARMACEUTICALS LTD GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDBROMHEXINE HYDROCHLORIDE SYRUP 8MG/5MLBROMHEXINE HYDROCHLORIDE SYRUP 4MG/5ML | $656.0K | 5 | 4.0% |
| 7 | GLENMARK PHARMACEUTICALS LIMITED GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDLAMOXY BX CAPSULES 500 MGASCORIL TABLETS KH 10X1X10'S | $595.1K | 7 | 3.7% |
| 8 | SANPRAS HEALTHCARE PRIVATE LIMITED BROMHEXINE SYRUP 4MG/5ML (BROMHEXINA JBEBROMHEXINE SYRUP 4MG/5ML (BROMHXINA JBE.BROMHEXINE HYDROCHLORIDE SYRUP 4MG/5ML, | $359.7K | 2 | 2.2% |
| 9 | MEDREICH LIMITED CETYLPYRIDINIUM CHLORIDE AND BROMHEXINE | $337.7K | 2 | 2.1% |
| 10 | IPCA LABORATORIES LIMITED | $308.0K | 3 | 1.9% |
| 11 | LABORATE PHARMACEUTICALS INDIA LTD | $287.8K | 3 | 1.8% |
| 12 | ADCOCK INGRAM LIMITED CETYLPYRIDINIUM CHLORIDE AND BROMHEXINE | $269.6K | 2 | 1.7% |
| 13 | GRACURE PHARMACEUTICALS LIMITED CETYLPYRIDINIUM CHLORIDE AND BROMHEXINE | $254.0K | 2 | 1.6% |
| 14 | S.D.PHARMACEUTICALS BROMHEXINE HYDROCHLORIDE SYRUP 8MG/5MLBROMHEXINE HYDROCHLORIDE SYRUP 4MG/5ML | $225.0K | 1 | 1.4% |
| 15 | BAROQUE PHARMACEUTICALS PVT LTD BROMHEXINE SYRUP 4MG/5ML (BROMHEXINA JBEBROMHEXINE SYRUP 4MG/5ML (BROMHXINA JBE.BROMHEXINE HYDROCHLORIDE SYRUP 4MG/5ML, | $218.0K | 1 | 1.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bromhexine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | Received FDA warning letter for CGMP violations at Pithampur facility. |
| Emcure Pharmaceuticals Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | FDA issued warning letter for repeated CGMP violations at Pune facility. |
| Cipla Limited | Warning Letter (November | Unknown | Unknown | Not verified | FDA warning letter for CGMP violations at Pithampur facility. |
| Jagsonpal Pharmaceuticals Limited | Warning Letter (February | Unknown | Unknown | Not verified | FDA warning letter for CGMP deviations at Bhiwadi facility. |
| Eugia Pharma Specialities Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | FDA warning letter for CGMP violations at Hyderabad facility. |
| Unexo Lifesciences Private Limited | Warning Letter (November | Unknown | Unknown | Not verified | FDA warning letter for CGMP violations at New Delhi facility. |
| Global Pharma Healthcare Private Limited | Warning Letter (October 2 | Unknown | Unknown | Not verified | FDA warning letter for CGMP violations at Thiruporur facility. |
TransData Nexus reviewed the regulatory standing of 7 leading Bromhexine exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 7 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bromhexine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts more than 2,000 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The Hyderabad Pharma City project, recognized as a National Investment Manufacturing Zone in December 2019, aims to further bolster this sector.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Vadodara, in particular, is home to numerous pharmaceutical companies, making it a significant hub in Gujarat's pharmaceutical industry. The region's focus on formulations complements Hyderabad's bulk drug production, creating a comprehensive pharmaceutical supply chain.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to various international markets. The region's well-established infrastructure and proximity to international shipping routes make it an ideal hub for pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production facilities, thereby contributing significantly to India's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different pharmaceutical clusters to mitigate risks associated with regional disruptions.
- Leverage Regional Strengths: Source bulk drugs from Hyderabad and formulations from the Ahmedabad-Vadodara corridor to capitalize on regional specializations.
- Optimize Logistics: Utilize the Mumbai-Thane-Raigad region's export infrastructure to streamline international shipments.
- Evaluate Cost Benefits: Consider manufacturing in the Baddi-Nalagarh region to take advantage of tax incentives and reduce production costs.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bromhexine exporters from India
Emcure Pharmaceuticals Limited — Emcure partners with Sanofi for exclusive product distribution in India
On March 13, 2024, Emcure Pharmaceuticals entered into agreements with Sanofi India Ltd and Sanofi Healthcare India Pvt Ltd to exclusively distribute and promote Sanofi's products, including brands such as Cardace, Clexane, Targocid, Lasix, Lasilactone, Cordarone, Plavix, and Synvisc, in India. - IMPACT: This collaboration is expected to enhance Emcure's domestic market presence, potentially increasing resources for Bromhexine export operations.
Impact: This collaboration is expected to enhance Emcure's domestic market presence, potentially increasing resources for Bromhexine export operations.
Common Questions — Bromhexine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bromhexine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, UMAVIDA PHARMA PRIVATE LIMITED leads with 53 recorded shipments worth $2.6M. EMCURE PHARMACEUTICALS LIMITED (119 shipments) and MAXFORD HEALTHCARE (6 shipments) are also established high-volume exporters.
Q How many bromhexine manufacturers are there in India?
India has 288 active bromhexine exporters with a combined export market of $16.3M across 1,945 shipments to 109 countries. The top 5 suppliers hold 45.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bromhexine from India?
Average FOB unit price: $3.40 per unit, ranging from $0.00 to $1073.19. Average shipment value: $8.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 288 verified Indian exporters of Bromhexine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,945 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 109 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,945 Verified Shipments
288 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists